Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study

Oncotarget

Volumn 7, Issue 27, 2016, Pages 41575-41583

  Cao, Zhe ^a   Liu, Chang ^b   Xu, Jianwei ^c   You, Lei ^a   Wang, Chunyou ^d   Lou, Wenhui ^e   Sun, Bei ^f   Miao, Yi ^g   Liu, Xubao ^h   Wang, Xiaowo ^b   Zhang, Taiping ^a   Zhao, Yupei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b TSINGHUA UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e FUDAN UNIVERSITY   (China)

^f HARBIN MEDICAL UNIVERSITY   (China)

^g NANJING MEDICAL UNIVERSITY   (China)

^h SICHUAN UNIVERSITY   (China)

Author keywords

Diagnosis; MicroRNA panels; Multicenter study; Pancreatic cancer

Indexed keywords

MICRORNA; TRANSCRIPTOME; TUMOR MARKER;

BLOOD; BLOOD ANALYSIS; CASE CONTROL STUDY; CHINA; CHRONIC PANCREATITIS; CLINICAL TRIAL; EARLY CANCER DIAGNOSIS; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDY; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; MALE; MULTICENTER STUDY; PANCREAS TUMOR; PROCEDURES; VALIDATION STUDY;

BIOMARKERS, TUMOR; BLOOD CHEMICAL ANALYSIS; CASE-CONTROL STUDIES; CHINA; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MALE; MICRORNAS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; TRANSCRIPTOME;

EID: 85008912679     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9491     Document Type: Article

References (42)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015.CA Cancer J Clin.2015; 65:5-29.
2. Costello E, Neoptolemos JP. Pancreatic cancer in 2010: new insights for early intervention and detection. Nature reviews Gastroenterology & hepatology. 2011; 8:71-73.
3. Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology. 2013; 144:1316-1326.
4. Sohal DP, Walsh RM, Ramanathan RK, Khorana AA. Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy. Journal of the National Cancer Institute. 2014; 106:dju011.
5. Atkins CD. CA 19-9 and Lewis antigens in pancreatic cancer. Journal of clinical oncology. 2009; 27:2572-2573; author reply 2573.
6. von Rosen A, Linder S, Harmenberg U, Pegert S. Serum levels of CA 19-9 and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease. Pancreas. 1993; 8:160-165.
7. Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. Journal of surgical oncology. 2013; 107:15-22.
8. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO molecular medicine. 2012; 4:143-159.
9. Chitkara D, Mittal A, Mahato RI. miRNAs in pancreatic cancer: therapeutic potential, delivery challenges and strategies. Advanced drug delivery reviews. 2015; 81:34-52.
10. Wang P, Zhang L, Chen Z, Meng Z. MicroRNA targets autophagy in pancreatic cancer cells during cancer therapy. Autophagy. 2013; 9:2171-2172.
11. Schultz NA, Werner J, Willenbrock H, Roslind A, Giese N, Horn T, Wojdemann M, Johansen JS. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Modern pathology. 2012; 25:1609-1622.
12. Szafranska AE, Doleshal M, Edmunds HS, Gordon S, Luttges J, Munding JB, Barth RJ, Jr., Gutmann EJ, Suriawinata AA, Marc Pipas J, Tannapfel A, Korc M, Hahn SA, et al. Analysis of microRNAs in pancreatic fineneedle aspirates can classify benign and malignant tissues. Clinical chemistry. 2008; 54:1716-1724.
13. Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG, Maitra A. Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology. 2010; 10:66-73.
14. du Rieu MC, Torrisani J, Selves J, Al Saati T, Souque A, Dufresne M, Tsongalis GJ, Suriawinata AA, Carrere N, Buscail L, Cordelier P. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clinical chemistry. 2010; 56:603-612.
15. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nature reviews Clinical oncology. 2014; 11:145-156.
16. Xu J, Cao Z, Liu W, You L, Zhou L, Wang C, Lou W, Sun B, Miao Y, Liu X, Zhang T, Zhao Y. Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study. Annals of surgery. 2016; 263(6):1173-9.
17. Ali S, Saleh H, Sethi S, Sarkar FH, Philip PA. MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. British journal of cancer. 2012; 107:1354-1360.
18. Patnaik SK, Yendamuri S, Kannisto E, Kucharczuk JC, Singhal S, Vachani A. MicroRNA expression profiles of whole blood in lung adenocarcinoma. PloS one. 2012; 7:e46045.
19. Fassina A, Marino F, Siri M, Zambello R, Ventura L, Fassan M, Simonato F, Cappellesso R. The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. Laboratory investigation. 2012; 92:1574-1582.
20. Vosa U, Vooder T, Kolde R, Vilo J, Metspalu A, Annilo T. Meta-analysis of microRNA expression in lung cancer. International journal of cancer 2013; 132:2884-2893.
21. Ko AH. Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. Journal of clinical oncology. 2015; 33:1779-1786.
22. Costello E, Greenhalf W, Neoptolemos JP. New biomarkers and targets in pancreatic cancer and their application to treatment. Nature reviews Gastroenterology & hepatology. 2012; 9:435-444.
23. Rachagani S, Macha MA, Heimann N, Seshacharyulu P, Haridas D, Chugh S, Batra SK. Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. Advanced drug delivery reviews. 2015; 81:16-33.
24. Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, Hu Z, Zhuang R, Ning G, Zhang C, Yuan Y, Li Z, Zen K, et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clinical chemistry. 2012; 58:610-618.
25. Liu J, Gao J, Du Y, Li Z, Ren Y, Gu J, Wang X, Gong Y, Wang W, Kong X. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. International journal of cancer 2012; 131:683-691.
26. Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz M, Hollander NH, Andersen KK, Johansen JS. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. Jama. 2014; 311:392-404.
27. Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, Goggins M. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with lowstage pancreatic cancer from healthy and disease controls. Clinical cancer research. 2013; 19:3600-3610.
28. Mees ST, Mardin WA, Sielker S, Willscher E, Senninger N, Schleicher C, Colombo-Benkmann M, Haier J. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Annals of surgical oncology. 2009; 16:2339-2350.
29. Tai HC, Chang AC, Yu HJ, Huang CY, Tsai YC, Lai YW, Sun HL, Tang CH, Wang SW. Osteoblast-derived WNTinduced secreted protein 1 increases VCAM-1 expression and enhances prostate cancer metastasis by down-regulating miR-126. Oncotarget. 2014; 5:7589-7598. doi: 10.18632/ oncotarget.2280.
30. Wang CZ, Yuan P, Li Y. MiR-126 regulated breast cancer cell invasion by targeting ADAM9. International journal of clinical and experimental pathology. 2015; 8:6547-6553.
31. Watahiki A, Macfarlane RJ, Gleave ME, Crea F, Wang Y, Helgason CD, Chi KN. Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. International journal of molecular sciences. 2013; 14:7757-7770.
32. Yan W, Liu Y, Yang P, Wang Z, You Y, Jiang T. MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype. Oncotarget. 2015; 6:11676-11682. doi: 10.18632/oncotarget.3258.
33. Butz H, Liko I, Czirjak S, Igaz P, Korbonits M, Racz K, Patocs A. MicroRNA profile indicates downregulation of the TGFbeta pathway in sporadic non-functioning pituitary adenomas. Pituitary. 2011; 14:112-124.
34. Williams TM, Flecha AR, Keller P, Ram A, Karnak D, Galban S, Galban CJ, Ross BD, Lawrence TS, Rehemtulla A, Sebolt-Leopold J. Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer. Molecular cancer therapeutics. 2012; 11:1193-1202.
35. Baumgart S, Chen NM, Siveke JT, Konig A, Zhang JS, Singh SK, Wolf E, Bartkuhn M, Esposito I, Hessmann E, Reinecke J, Nikorowitsch J, Brunner M, et al. Inflammationinduced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. Cancer discovery. 2014; 4:688-701.
36. Briest F, Grabowski P. PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms. Theranostics. 2014; 4:336-365.
37. Sharma N, Nanta R, Sharma J, Gunewardena S, Singh KP, Shankar S, Srivastava RK. PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth. Oncotarget. 2015; 6:32039-32060. doi: 10.18632/ oncotarget.5055.
38. Soares HP, Ming M, Mellon M, Young SH, Han L, Sinnet- Smith J, Rozengurt E. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2. Molecular cancer therapeutics. 2015; 14:1014-1023.
39. Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. Journal of clinical oncology. 2015; 33:1770-1778.
40. Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013; 63:318-348.
41. Conwell DL, Lee LS, Yadav D, Longnecker DS, Miller FH, Mortele KJ, Levy MJ, Kwon R, Lieb JG, Stevens T, Toskes PP, Gardner TB, Gelrud A, et al. American Pancreatic Association Practice Guidelines in Chronic Pancreatitis: evidence-based report on diagnostic guidelines. Pancreas. 2014; 43:1143-1162.
42. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC bioinformatics. 2011; 12:77.